Immunogen Inc
IMGN
IMGN was delisted on the 9th of February, 2024.
217 hedge funds and large institutions have $922M invested in Immunogen Inc in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 74 increasing their positions, 64 reducing their positions, and 43 closing their positions.
318% more call options, than puts
Call options by funds: $7.09M | Put options by funds: $1.7M
16% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 64
8% less funds holding
Funds holding: 236 → 217 (-19)
33% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 43
34% less capital invested
Capital invested by funds: $1.41B → $922M (-$484M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$31.2M |
| 2 |
DM
Deerfield Management
New York
|
+$19.2M |
| 3 |
BlackRock
New York
|
+$8.69M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.3M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$28.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$28.7M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$15.4M |
| 4 |
Millennium Management
New York
|
-$8.58M |
| 5 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$6.47M |
IMGN Hedge Fund Activity: Q1 2022 in Review
217 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q1 2022, worth a combined $922M — down 34% from $1.41B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of IMGN and 29 opened new positions — a net loss of 14 holders — while 64 trimmed existing stakes and 74 added.
The largest buyer was State Street, adding an estimated $31.2M. The largest seller was OrbiMed, exiting entirely with an estimated $28.7M sold.
- 217 institutional investors held Immunogen Inc (IMGN) as of Q1 2022, down from 236 in Q4 2021.
- Funds reported $922M of Immunogen Inc stock for Q1 2022, down 34% quarter-over-quarter.
- 29 funds opened new Immunogen Inc positions in Q1 2022 and 43 closed out, a net change of -14 holders.
- The largest Immunogen Inc buyer in Q1 2022 was State Street, an estimated $31.2M added.
- The largest Immunogen Inc seller in Q1 2022 was OrbiMed, an estimated $28.7M sold.
Based on aggregated 13F filings for Q1 2022.